(Q30275719)

English

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Vassiliki Papadimitrakopoulou

4

object named as

Vassiliki A Papadimitrakopoulou

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Shadia I. Jalal

10

object named as

Shadia I Jalal

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Lecia V Sequist

14

object named as

Lecia V Sequist

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Hossein Borghaei

3

object named as

Hossein Borghaei

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1

object named as

Corey J Langer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

Shirish M Gadgeel

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Amita Patnaik

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Steven F Powell

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Ryan D Gentzler

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Renato G Martins

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

James P Stevenson

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Amit Panwalkar

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

James Chih-Hsin Yang

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Matthew Gubens

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Mark M Awad

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Joseph Fiore

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Yang Ge

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Harry Raftopoulos

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

KEYNOTE-021 investigators

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

publication date

10 October 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1497-1508

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

On closed testing procedures with special reference to ordered analysis of variance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930498-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30498-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27745820%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30275719&oldid=1915882212"